Scemblix outperformed standard tyrosine kinase inhibitor treatment in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Frontline Scemblix (asciminib) improved outcomes over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results